Combined BRAF, EGFR, and MEK Inhibition in Patients with $BRAF^{V600E}$-Mutant Colorectal Cancer

**ABSTRACT**

Although BRAF inhibitor monotherapy yields response rates >50% in $BRAF^{V600E}$-mutant melanoma, only approximately 5% of patients with $BRAF^{V600E}$ colorectal cancer respond. Preclinical studies suggest that the lack of efficacy in $BRAF^{V600E}$ colorectal cancer is due to adaptive feedback reactivation of MAPK signaling, often mediated by EGFR. This clinical trial evaluated BRAF and EGFR inhibition with dabrafenib (D) + panitumumab (P) ± MEK inhibition with trametinib (T) to achieve greater MAPK suppression and improved efficacy in 142 patients with $BRAF^{V600E}$ colorectal cancer. Confirmed response rates for D+P, D+T+P, and T+P were 10%, 21%, and 0%, respectively. Pharmacodynamic analysis of paired pretreatment and on-treatment biopsies found that efficacy of D+T+P correlated with increased MAPK suppression. Serial cell-free DNA analysis revealed additional correlates of response and emergence of $KRAS$ and $NRAS$ mutations on disease progression. Thus, targeting adaptive feedback pathways in $BRAF^{V600E}$ colorectal cancer can improve efficacy, but MAPK reactivation remains an important primary and acquired resistance mechanism.

**SIGNIFICANCE:** This trial demonstrates that combined BRAF + EGFR + MEK inhibition is tolerable, with promising activity in patients with $BRAF^{V600E}$ colorectal cancer. Our findings highlight the MAPK pathway as a critical target in $BRAF^{V600E}$ colorectal cancer and the need to optimize strategies inhibiting this pathway to overcome both primary and acquired resistance.

_Cancer Discov; 8(4); 428–43._ © 2018 AACR.

See related commentary by Janku, p. 389.

See related article by Hazar-Rethinam et al., p. 417.
INTRODUCTION

Activating gene mutations in the MAPK pathway are frequently observed in cancer and promote tumor cell migration, proliferation, and survival (1, 2). The serine/threonine protein kinase BRAF belongs to the RAF family of kinases [including ARAF and CRAF (RAF1); refs. 1, 2], which are normally activated by RAS family members (KRAS, NRAS, and HRAS), typically in response to signals from receptor tyrosine kinases (RTK; refs. 2, 3). BRAF V600 mutations lead to constitutive, RAS-independent activation of BRAF kinase activity and MAPK pathway signaling through downstream activation of MEK (MEK1 and MEK2) and ERK (ERK1 and ERK2) kinases (2, 3).

Oncogenic BRAF V600E mutations are present in approximately 10% of colorectal cancers (2, 4) and approximately 50% of melanomas (5). In colorectal cancer, BRAF V600E mutations confer a poor prognosis, resulting in nearly a 2-fold increase in mortality relative to wild-type BRAF in the metastatic setting (1, 6, 7). BRAF V600E mutation in colorectal cancer is associated with a right-sided primary site, advanced age, female sex, high tumor grade, and precursor sessile serrated adenomas (8). BRAF V600E colorectal cancer is also associated with the CpG island methylator phenotype (i.e., hypermethylated phenotype), which may result in the epigenetic inactivation of MLH1, inducing a mismatch repair (MMR) deficiency and consequently a microsatellite instability (MSI) phenotype (9). Among patients harboring BRAF V600E metastatic colorectal cancer, approximately 20% exhibit deficient MMR deficiency (8). RAF inhibitors, such as vemurafenib and dabrafenib, selectively inhibit RAF monomers and have produced dramatic response rates >50% in metastatic melanoma, leading to their FDA approval for this indication (10, 11). However, single-agent BRAF inhibitors have demonstrated a surprising and striking lack of efficacy in patients with colorectal cancer harboring the same BRAF V600E mutation (12–16). Indeed, an initial study of vemurafenib in patients with the BRAF V600E mutation had a response rate of only 5% (16).

Preclinical studies have suggested that a primary reason for the differential sensitivities of BRAF V600E melanoma and colorectal cancer is that colorectal cancers harbor robust adaptive feedback signaling networks that lead to reactivation of MAPK signaling following BRAF inhibitor treatment (12, 15). In this proposed model, inhibition of BRAF V600E leads to an initial reduction in MAPK signaling, causing a loss of expression of ERK-dependent negative feedback mediators that act to constrain MAPK pathway activation (Fig. 1A; ref. 12). Loss of negative feedback leads to an induction of RAS activity and activation of other RAF kinases (such as
Corcoran et al.

Figure 1. Targeting adaptive feedback signaling in BRAFV600E colorectal cancer. A, Model of adaptive feedback signaling in BRAFV600E colorectal cancer. Left, in the absence of drug, MAPK activity is driven by mutant BRAF, and ERK-dependent–negative feedback signals constrain RTK-mediated activation of RAS. Center, BRAF inhibitor alone leads to transient inhibition of MAPK signaling and loss of ERK-dependent–negative feedback signals, allowing RTK-mediated reactivation of the MAPK pathway through RAF dimers (including BRAF and CRAF). Right, combined inhibition of BRAF, EGFR, and MEK is hypothesized to prevent adaptive feedback reactivation and maintain MAPK pathway suppression. B, Trial schematic showing treatment arms and dosing cohorts for treatment of patients with BRAFV600E colorectal cancer. Note that patients treated at doses of dabrafenib 150 mg twice a day (b.i.d.), trametinib 2 mg once a day (q.d.), and panitumumab at 6 mg/kg every 2 weeks (Q2W) or dabrafenib 150 mg b.i.d., trametinib 2 mg q.d., and panitumumab at 4.8 mg/kg Q2W were enrolled into the dose-escalation and dose-expansion phases of the trial.

CRAF), which bypass the effects of the BRAF inhibitor by generating BRAF inhibitor–resistant RAF dimers and restore MAPK pathway signaling (12). Increased RAS activity following BRAF inhibition is thought to be driven primarily by RTK signaling, which is present to a greater degree in colorectal cancer than in melanoma, and preclinical studies have suggested that one RTK in particular—the EGFR—may play a dominant role in mediating MAPK reactivation in many BRAFV600E colorectal cancers (12, 15). Indeed, the combination of BRAF and EGFR inhibition was found to produce improved MAPK suppression and lead to tumor regression in BRAFV600E colorectal cancer xenografts (12, 15).

Thus, these data suggest that therapies capable of blocking feedback reactivation may produce more robust inhibition of MAPK signaling, resulting in improved efficacy in BRAFV600E colorectal cancer. As an initial test of this hypothesis in BRAFV600E colorectal cancer, we previously performed a clinical trial of combined BRAF and MEK inhibition with dabrafenib and trametinib that demonstrated improved pathway suppression in preclinical models of
BRAF\textsuperscript{V600E} colorectal cancer (17). Indeed, this strategy has been successful in BRAF\textsuperscript{V600E/K} melanoma and BRAF\textsuperscript{V600E} non-small cell lung cancer, improving outcomes in patients who received the combination of dabrafenib and trametinib versus dabrafenib alone, leading to FDA approval for this combination in these indications (18–21). Combined BRAF and MEK inhibition led to a modestly improved response rate of 12% in 43 patients with BRAF\textsuperscript{V600E}-metastatic colorectal cancer, but analysis of paired pretreatment and on-treatment biopsy specimens suggested that MAPK pathway suppression remained suboptimal (17). Therefore, we hypothesized that targeting EGFR as a key mediator of feedback signaling in combination with a BRAF inhibitor, with or without a MEK inhibitor, may optimize MAPK pathway suppression and lead to improved efficacy in BRAF\textsuperscript{V600E} colorectal cancer (17).

Here, we report the results of a clinical trial of combined BRAF and EGFR inhibition, combined MEK and EGFR inhibition, and combined BRAF, EGFR, and MEK inhibition in patients with metastatic BRAF\textsuperscript{V600E} colorectal cancer. Paired pretreatment and on-treatment biopsy specimens were collected and analyzed to assess the pharmacodynamic effects of each therapy. Serial plasma specimens were obtained, and cell-free DNA (cfDNA) was analyzed to provide correlates of response and to identify mechanisms of acquired resistance.

**RESULTS**

**Patient Characteristics**

Between December 2012 and the time of data cutoff for this interim analysis (May 6, 2016), 142 patients with metastatic BRAF\textsuperscript{V600E} colorectal cancer were enrolled in 1 of 3 treatment arms, as outlined in Fig. 1B: Arm 1, combined BRAF and EGFR inhibition with dabrafenib and panitumumab (D+P, n = 20); Arm 2, the “triplet” combination of BRAF, MEK, and EGFR inhibition with dabrafenib, trametinib, and panitumumab (D+T+P, n = 91); and Arm 3, combined MEK and EGFR inhibition with trametinib and panitumumab (T+P, n = 31). Patient characteristics are shown in Table 1. In general, patient characteristics were well-balanced across groups.

**Dose Determination and Safety**

The initial dose assessment began with the evaluation of D+P at their full labeled doses [dabrafenib 150 mg orally twice a day (b.i.d.) and panitumumab 6 mg/kg i.v. every 2 weeks (Q2W)]. No dose-limiting toxicities (DLT) were observed, and a total of 20 patients were treated at this dose level. D+P was well tolerated, and the majority of events were grade 1 or 2; 45% of patients had a grade 3/4 event. The most common adverse events (AE) of all grades were dermatitis acneiform (60%), nausea (50%), fatigue (50%), and diarrhea (45%); none were grade 3/4 (Table 2). Only one grade 3/4 AE [hypophosphatemia: n = 2 (10%)] occurred in >1 patient in the D+P group.

Dose escalation to the full label doses of each of the triplet agents, D+T+P, was completed (dabrafenib 150 mg orally b.i.d., trametinib 2 mg orally daily, and panitumumab 6 mg/kg i.v. Q2W). A total of 48 patients were enrolled at the highest dose, and the spectrum of AEs was similar to that with D+P. Diarrhea (65% all grades, 7% grade 3/4), nausea (56% all grades, 2% grade 3/4), and dermatitis acneiform (59% all grades, 8% grade 3/4) were common adverse events. The incidence of grade 3/4 events was 5% (diabetes 4%, hypophosphatemia 4%, and hypertension 2%).

**Table 1. Patient demographics across treatment arms**

<table>
<thead>
<tr>
<th></th>
<th>D+P (n = 20)</th>
<th>T+P (n = 31)</th>
<th>D+T+P (n = 91)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, median (range), y</td>
<td>58.0 (42-84)</td>
<td>57.0 (39-74)</td>
<td>60.0 (28-83)</td>
</tr>
<tr>
<td>Female, n (%)</td>
<td>11 (55)</td>
<td>18 (58)</td>
<td>58 (64)</td>
</tr>
<tr>
<td>ECOG performance status at baseline, n (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0</td>
<td>13 (65)</td>
<td>17 (55)</td>
<td>47 (52)</td>
</tr>
<tr>
<td>1</td>
<td>7 (35)</td>
<td>14 (45)</td>
<td>44 (49)</td>
</tr>
<tr>
<td>Prior lines of therapy, n (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0</td>
<td>4 (20)</td>
<td>1 (3)</td>
<td>21 (23)</td>
</tr>
<tr>
<td>1</td>
<td>8 (40)</td>
<td>14 (45)</td>
<td>27 (30)</td>
</tr>
<tr>
<td>2</td>
<td>7 (35)</td>
<td>11 (35)</td>
<td>33 (36)</td>
</tr>
<tr>
<td>3</td>
<td>1 (5)</td>
<td>4 (13)</td>
<td>9 (10)</td>
</tr>
<tr>
<td>4</td>
<td>0</td>
<td>1 (3)</td>
<td>1 (1)</td>
</tr>
<tr>
<td>5</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Prior anti-EGFR therapy, n (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>1 (5)</td>
<td>10 (32)</td>
<td>13 (14)</td>
</tr>
<tr>
<td>No</td>
<td>19 (95)</td>
<td>21 (68)</td>
<td>78 (86)</td>
</tr>
<tr>
<td>Primary tumor location, n (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Colon</td>
<td>18 (90)</td>
<td>26 (84)</td>
<td>76 (84)</td>
</tr>
<tr>
<td>Left side</td>
<td>4 (22)</td>
<td>10 (38)</td>
<td>19 (25)</td>
</tr>
<tr>
<td>Right side</td>
<td>14 (78)</td>
<td>16 (62)</td>
<td>57 (75)</td>
</tr>
<tr>
<td>Rectum</td>
<td>2 (10)</td>
<td>5 (16)</td>
<td>15 (16)</td>
</tr>
</tbody>
</table>

Abbreviation: ECOG, Eastern Cooperative Oncology Group.
Corcoran et al.

Table 2. AEs occurring in >30% of patients in any treatment arm

<table>
<thead>
<tr>
<th>AE, n (%)</th>
<th>D+P (n = 20)</th>
<th>T+P (n = 51)</th>
<th>D+T+P (n = 91)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Total</td>
<td>Grade 3/4</td>
<td>Total</td>
</tr>
<tr>
<td>Any event</td>
<td>20 (100)</td>
<td>9 (45)</td>
<td>50 (98)</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>9 (45)</td>
<td>0</td>
<td>37 (73)</td>
</tr>
<tr>
<td>Dermatitis acneiform</td>
<td>12 (60)</td>
<td>0</td>
<td>27 (53)</td>
</tr>
<tr>
<td>Nausea</td>
<td>10 (50)</td>
<td>0</td>
<td>18 (35)</td>
</tr>
<tr>
<td>Dry skin</td>
<td>7 (35)</td>
<td>1 (5)</td>
<td>17 (33)</td>
</tr>
<tr>
<td>Fatigue</td>
<td>10 (50)</td>
<td>0</td>
<td>13 (25)</td>
</tr>
<tr>
<td>Pyrexia</td>
<td>7 (35)</td>
<td>0</td>
<td>20 (39)</td>
</tr>
<tr>
<td>Vomiting</td>
<td>6 (30)</td>
<td>0</td>
<td>15 (29)</td>
</tr>
<tr>
<td>Decreased appetite</td>
<td>5 (25)</td>
<td>0</td>
<td>12 (24)</td>
</tr>
<tr>
<td>Rash</td>
<td>3 (15)</td>
<td>0</td>
<td>16 (31)</td>
</tr>
<tr>
<td>Hypomagnesemia</td>
<td>8 (40)</td>
<td>1 (5)</td>
<td>12 (24)</td>
</tr>
<tr>
<td>Constipation</td>
<td>7 (35)</td>
<td>1 (5)</td>
<td>7 (14)</td>
</tr>
</tbody>
</table>

aSafety data were based on the most recent interim analyses (data cutoff May 6, 2016). The median follow-up time (defined as time in months from study start to last contact or death) for patients treated with D+P was 10.6 months (2.1–22 months), for patients treated with D+T+P was 6.2 months (1.5–4.72 months), and for patients with a BRAFV600E mutation treated with T+P was 6.4 months (0.4–18.6 months).

bSafety data for the T+P arm are for all patients, including those with BRAF wild-type (n = 20) and BRAFV600E (n = 31).

Table 3. Efficacy measures for the 3 treatment arms

<table>
<thead>
<tr>
<th>Treatment Arm</th>
<th>CR/PR (n)</th>
<th>SD (n)</th>
<th>PD (n)</th>
<th>TTF (months)</th>
<th>OS (months)</th>
</tr>
</thead>
<tbody>
<tr>
<td>D+P</td>
<td>2 (10)</td>
<td>13 (65)</td>
<td>7 (35)</td>
<td>3.5</td>
<td>13.2</td>
</tr>
<tr>
<td>T+P</td>
<td>0 (0)</td>
<td>32 (63)</td>
<td>19 (37)</td>
<td>4.0</td>
<td>9.1</td>
</tr>
<tr>
<td>D+T+P</td>
<td>2 (2)</td>
<td>35 (38)</td>
<td>54 (62)</td>
<td>4.2</td>
<td>9.1</td>
</tr>
</tbody>
</table>

Efficacy

Efficacy measures for the 3 treatment arms are also based on a data cutoff date of May 6, 2016 (Fig. 2A–C). Two patients (10%) in the D+P arm had a confirmed complete response (CR) or partial response (PR), and 16 patients (80%) had stable disease; disease control was 90% overall. In the T+P arm, no patients achieved CR/PR, and 17 patients (55%) had stable disease. The D+T+P arm resulted in a confirmed CR/PR in 19 patients (21%), stable disease in 59 patients (65%), and an overall disease control rate of 86%. Duration of response (DOR) in the D+T+P arm was estimable but not mature, with a median of 7.6 months [95% confidence interval (CI), 2.9–not evaluable months; Table 3].

The median progression-free survival (PFS) was 3.5 months (95% CI, 2.8–5.8 months) in the D+P arm, 2.6 months (95% CI, 1.4–2.8 months) in the T+P arm, and 4.2 months (95% CI, 4.0–5.6 months) in the D+T+P arm (Fig. 2D). Median overall survival (OS) was 13.2 months (95% CI, 6.7–22.0 months) in the D+P arm, 8.2 months (95% CI, 6.5–9.4 months) in the T+P arm, and 9.1 months (95% CI, 7.6–20.0 months) in the D+T+P arm (estimable but not mature; Supplementary Fig. S1).
Figure 2. Efficacy of D+P, T+P, and D+T+P in patients with BRAFV600E colorectal cancer. A–C, Waterfall plots showing best response by RECIST in the D+P (A), T+P (B), and D+T+P (C) cohorts. Dotted lines represent the 30% threshold for PR. Bar color represents the best confirmed response by RECIST. D, PFS for the D+P, T+P, and D+T+P cohorts. Median PFS with 95% CIs are shown for each treatment arm.
Target Engagement: Pharmacodynamic Analysis of Paired Tumor Biopsy Specimens

Per the protocol, paired fresh tumor biopsy specimens obtained before treatment (within 3 weeks of treatment start) and on day 15 of treatment were required for all patients enrolled. Pharmacodynamic markers were analyzed in 10, 21, and 26 paired biopsy specimens collected from patients in the D+P, T+P, and D+T+P arms, respectively. The effect of each therapy on MAPK signaling output [assessed as the change in phosphorylated ERK (pERK) levels by immunohistochemistry from the day 15 on-treatment biopsy specimen], relative to the pretreatment biopsy, was evaluated. Values were compared from the day 15 on-treatment biopsy specimen, relative to the phosphorylated ERK (pERK) levels by immunohistochemistry.

We used a highly sensitive method for the detection of tumor-derived mutations in cfDNA termed BEAMing (Beads, Research.

### Table 3. Summary of efficacy by treatment cohort (investigator review)

<table>
<thead>
<tr>
<th>Assessment</th>
<th>D+T+P (n=91)</th>
<th>T+P (n=31)</th>
<th>D+P (n=20)</th>
<th>D+T (n=43)*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Best confirmed response, n (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CR</td>
<td>1 (1)</td>
<td>0</td>
<td>1 (5)</td>
<td>1 (2)</td>
</tr>
<tr>
<td>PR</td>
<td>18 (20)</td>
<td>0</td>
<td>1 (5)</td>
<td>2 (5)</td>
</tr>
<tr>
<td>SD</td>
<td>59 (65)</td>
<td>17 (55)</td>
<td>16 (80)</td>
<td>24 (56)</td>
</tr>
<tr>
<td>PD</td>
<td>8 (9)</td>
<td>12 (39)</td>
<td>2 (10)</td>
<td>10 (23)</td>
</tr>
<tr>
<td>NE</td>
<td>5 (5)</td>
<td>2 (6)</td>
<td>0</td>
<td>6 (14)</td>
</tr>
<tr>
<td>ORR (CR + PR), n (%) (95% CI)</td>
<td>19 (21) (13.1–30.7)</td>
<td>0 (0–11.2)</td>
<td>2 (10) (1.2–31.7)</td>
<td>3 (7)</td>
</tr>
<tr>
<td>DOR (95% CI), months</td>
<td>7.6 (2.9–NR)</td>
<td>0</td>
<td>6.9 (5.9–8.0)</td>
<td>–</td>
</tr>
<tr>
<td>DCR (CR + PR + SD), %</td>
<td>86</td>
<td>55</td>
<td>90</td>
<td>68</td>
</tr>
<tr>
<td>Median PFS, months</td>
<td>4.2</td>
<td>2.6</td>
<td>3.5</td>
<td>3.5</td>
</tr>
<tr>
<td>Unconfirmed CR + PR, n (%)</td>
<td>29 (32)</td>
<td>1 (3)</td>
<td>3 (15)</td>
<td>5 (12)</td>
</tr>
</tbody>
</table>

Abbreviations: DCR, disease control rate; NE, not evaluable; NR, not reached; ORR, overall response rate; PD, progressive disease; SD, stable disease.

*Key efficacy measures are shown across treatment arms. Efficacy data for patients treated with D+T (ref. 17) are shown for comparison.
Figure 3. Pharmacodynamic analysis of paired tumor biopsy specimens. A, H-scores for pERK in paired baseline and day 15 on-treatment tumor biopsy specimens from patients treated with D+P, T+P, and D+T+P. P values represent the paired t test. B, The percentage change in pERK H-score in the on-treatment tumor biopsy specimen relative to the baseline biopsy specimen in individual patients according to treatment. The percentage change in pERK H-score in paired on-treatment biopsy specimens for patients with BRAC600E colorectal cancer treated with D+T and BRAFV600E, mutant melanoma treated with dabrafenib alone are shown for comparison. Horizontal bars represent the median.

**A**

<table>
<thead>
<tr>
<th>Treatment</th>
<th>N</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>D+P</td>
<td>10</td>
<td>0.5</td>
</tr>
<tr>
<td>T+P</td>
<td>21</td>
<td>0.002</td>
</tr>
<tr>
<td>D+T+P</td>
<td>26</td>
<td>0.002</td>
</tr>
</tbody>
</table>

**B**

<table>
<thead>
<tr>
<th>Treatment</th>
<th>N</th>
<th>pERK modulation, %</th>
</tr>
</thead>
<tbody>
<tr>
<td>D (melanoma)</td>
<td>8</td>
<td>-83.889</td>
</tr>
<tr>
<td>D+T</td>
<td>9</td>
<td>-36.718</td>
</tr>
<tr>
<td>D+P</td>
<td>10</td>
<td>-23.0357</td>
</tr>
<tr>
<td>T+P</td>
<td>20</td>
<td>-41.1628</td>
</tr>
<tr>
<td>D+T+P</td>
<td>25</td>
<td>-60</td>
</tr>
</tbody>
</table>

*a* Data from Falchook GS, et al. (ref. 22)

*b* Data from Corcoran RB, et al. (ref. 17)
Emulsion, and Magnetics) to monitor changes in the levels of $BRAF_{V600E}$ in blood during treatment (26). $BRAF_{V600E}$ levels were analyzed in plasma from 85 patients treated with D+T+P; 71 of 85 patients had $BRAF$ mutations detected by BEAMing at baseline (83.5%). A marked decrease in $BRAF_{V600E}$ levels in cfDNA from baseline was noted by 4 weeks in patients achieving a PR or CR with D+T+P, with all but 1 patient exhibiting reductions of >95%. The decrease in $BRAF_{V600E}$ levels was significantly greater in patients with responses than in patients with stable or progressive disease ($P = 0.004$) and was correlated significantly with the best percentage tumor change ($P = 0.001$, $R = 0.414$; Fig. 4A and B). These results suggest that serial monitoring of $BRAF_{V600E}$ levels in cfDNA at baseline and on treatment may be a clinically useful marker of tumor response.

We compared the predictive value of $BRAF_{V600E}$ levels in cfDNA with serum levels of carcinoembryonic antigen (CEA), which is commonly used as a blood-based tumor marker in patients with colorectal cancer as part of standard clinical practice. The $BRAF_{V600E}$ mutation was detectable in 71 of 85 (84%) evaluable patients; however, elevated CEA levels were detected in only 68 of 126 (54%) evaluable patients across arms and in 43 of 81 (53%) evaluable patients in the D+T+P arm. In contrast with $BRAF_{V600E}$ levels in cfDNA, the change in CEA levels by 6 weeks of treatment was not statistically significant between patients who achieved CR/PR and those with stable or progressive disease (Fig. 4A). In serial blood collections obtained throughout therapy, a consistent rebound in $BRAF_{V600E}$ levels was observed in cfDNA at the time of disease progression, whereas a consistent pattern was not observed with CEA levels (Fig. 4C). Taken together, these data suggest that monitoring $BRAF_{V600E}$ levels in cfDNA during therapy correlates well with response and disease trajectory in patients with $BRAF_{V600E}$-mutant colorectal cancer, and that cfDNA was more informative than CEA—the standard clinical tumor marker for colorectal cancer.

cfDNA analysis can also be an effective tool for identifying and detecting mechanisms of acquired resistance to therapy (27–31). Prior studies have revealed that acquired resistance to BRAF-directed therapy in patients with $BRAF_{V600E}$ colorectal cancer is frequently driven by genomic alterations (e.g., $RAS$ mutations), which lead to reactivation of MAPK signaling (28, 32, 33). We used a BEAMing panel to detect the presence of 11 common hot-spot mutations in $KRAS$ and $NRAS$.

Figure 4. Serial cfDNA analysis to define correlates of response and resistance. A, Percentage change in $BRAF_{V600E}$ mutation levels in cfDNA (week 4 vs. baseline) or CEA levels (week 6 vs. baseline) for patients achieving CR/PR, stable disease (SD), or progressive disease (PD). CEA analysis was limited to patients with baseline levels above the upper limit of normal. $P$ values represent CR/PR vs. SD/PD by two-tailed $t$ test. B, Scatter plot of correlation between change in $BRAF_{V600E}$ mutation levels in cfDNA (week 4 vs. baseline) or CEA levels (week 6 vs. baseline) vs. best percentage tumor change. Color of dots indicates the level of response achieved. (continued on following page)
BRAF/EGFR/MEK Inhibition in BRAF\textsuperscript{V600E} Colorectal Cancer

C

Complete or partial response

Stable disease

Progressive disease

Figure 4. (Continued) C, Spider plots showing BRAF\textsuperscript{V600E} mutation levels in cfDNA or CEA levels (normalized to baseline measurement) during therapy for patients achieving CR/PR, SD, or PD. D, Three representative patients treated with D+T+P with serial cfDNA monitoring of BRAF\textsuperscript{V600E} mutation levels and hot-spot KRAS and NRAS mutations at baseline, at week 4 of therapy, and at time of PD, showing emergence of 1 or more KRAS or NRAS mutations.

(see Methods for further details) in cfDNA before treatment, during treatment, and at disease progression. We observed that, of the 29 evaluable patients who achieved a response (CR or PR) or stable disease with D+T+P and had cfDNA data available at the time of progression, 14 patients (48%) developed \( \geq 1 \) detectable KRAS or NRAS mutation in cfDNA at the time of disease progression, which was not detectable at baseline. As shown in Fig. 4D, the initial decrease in BRAF\textsuperscript{V600E} mutation levels after initiation of therapy in these patients was followed by an eventual rebound in BRAF\textsuperscript{V600E} levels on disease progression, accompanied by the emergence of \( \geq 1 \) KRAS or NRAS mutation. In 6 of 29 patients (21%), \( >1 \) subclonal RAS mutation was observed on disease progression, suggesting the potential for tumor heterogeneity in the context of acquired resistance to therapy.

**DISCUSSION**

We present the results of a clinical trial of combined BRAF and EGFR inhibition with or without MEK inhibition in...
**BRAF**

**V600E** colorectal cancer. The trial was designed to target the key adaptive feedback pathways driving primary resistance to BRAF inhibition alone. Both combined BRAF and EGFR inhibition (with D+P) and combined BRAF, EGFR, and MEK inhibition (with D+T+P) were tolerated at the full label doses of all agents. However, the frequency and severity of AEs were greater in the D+T+P arm than in the D+P arm, most notably in terms of dermatologic toxicity. Remarkably, although all three agents were tolerated together at full dose, combined EGFR and MEK inhibition only (T+P) was not tolerated at full dose, due to dermatologic toxicity. Although this may be considered counterintuitive, it highlights the unique biology of the MAPK pathway and its key implications for therapy. Although BRAF inhibitors effectively suppress MAPK signaling by mutant **BRAF**

**V600E** monomers in tumor cells, they do not inhibit the MAPK pathway in normal cells, where RAF signals as a RAS-dependent dimer and paradoxically activates MAPK signaling (34–36). This activation underlies the frequent development of MAPK-driven tumors (e.g., proliferative skin lesions and secondary cutaneous malignancies) in patients receiving BRAF inhibitor monotherapy (37). Thus, BRAF inhibitors exhibit greater selectivity than other MAPK pathway inhibitors, allowing a greater degree of specific tumor MAPK suppression with less systemic toxicity; conversely, agents that inhibit MAPK signaling in all cells (such as MEK inhibitors) have greater systemic toxicity, limiting the achievable dose in patients and resulting in suboptimal MAPK inhibition in tumor cells. Moreover, the potential opposing effects of BRAF and MEK or EGFR inhibitors in normal cells likely counteract the effects on the MAPK pathway, providing a mechanistic explanation for the decreased toxicity seen with the triplet regimen in this trial. Taken together, these data illustrate how the therapeutic window advantages offered by BRAF inhibitors make them key components of therapeutic combinations for **BRAF**

**V600E** cancers.

Modest clinical activity was seen in the D+P arm, compared with reported response rates with BRAF inhibitor monotherapy; the confirmed response rate was 10%, whereas 15% were unconfirmed. These data are consistent with the efficacy reported for similar BRAF/EGFR inhibitor combinations (13, 38–40). Notably, a recent update of a study evaluating cetuximab + irinotecan with or without the BRAF inhibitor vemurafenib demonstrated that in patients treated with the triple combination, response rate was 16% (n = 44 evaluable patients), with a median PFS of 4.3 months among all patients in this arm (n = 49; ref. 40). Despite preclinical studies supporting EGFR as the primary driver of MAPK reactivation in **BRAF**

**V600E** colorectal cancer (12, 15), these data suggest that EGFR may be a critical mediator of resistance but that many patients may harbor other redundant mechanisms of adaptive MAPK reactivation. Consistent with this hypothesis, we observed that D+P led to MAPK suppression in on-treatment tumor biopsy specimens in only a subset of patients, suggesting that EGFR-independent mechanisms of MAPK reactivation play an important role in this disease. In support of this, some **BRAF**

**V600E** colorectal cancers do not express elevated levels of EGFR, and **BRAF**

**V600E** colorectal cancer cell lines have been identified in which MAPK reactivation and resistance are driven by RTKs other than EGFR, such as MET (12, 41). Collectively, these data support the need to inhibit both EGFR-dependent and EGFR-independent feedback signals in **BRAF**

**V600E** colorectal cancer.

Combined BRAF, MEK, and EGFR inhibition with D+T+P demonstrated increased efficacy, with confirmed and unconfirmed response rates of 21% and 32%, respectively—these figures being one of the highest response rates observed with any regimen to date in **BRAF**

**V600E**-mutant colorectal cancer (16, 17). Consistent with the potential importance of inhibiting EGFR-dependent and EGFR-independent feedback signals, D+T+P produced the greatest degree of MAPK pathway suppression in on-treatment biopsy specimens. However, D+T+P still produced suboptimal MAPK suppression when compared with dabrafenib alone in **BRAF**

**V600E**-mutant melanoma, providing a possible explanation for why the efficacy of this triplet in colorectal cancer still falls short of BRAF inhibitors alone in melanoma. This observation may also support the existence of adaptive feedback signals capable of overcoming the D+T+P triplet to drive MAPK reactivation and primary resistance to therapy. Therefore, developing therapeutic strategies that can overcome these signals and optimize MAPK pathway inhibition will be key.

In addition to driving primary resistance, our data also suggest that MAPK reactivation is a key mechanism of secondary or acquired resistance to therapy in **BRAF**

**V600E** colorectal cancer. We and others have reported that acquired resistance to BRAF inhibitor combinations in **BRAF**

**V600E** colorectal cancer can be driven by an array of alterations in MAPK pathway components and lead to pathway reactivation, including RTK amplification, RAS mutation or amplification, **BRAF**

**V600E** amplification, and MEK mutations. This finding also highlights the critical importance of MAPK signaling in these cancers (28, 32, 33, 42). Here, in a larger cohort of patients, we observed that almost half of patients (48%) demonstrated emergence of **KRAS** or **NRAS** mutations in cfDNA at the time of disease progression. MAPK pathway alterations may be present in an even larger percentage of patients, because the cfDNA panel used detects only a limited number of mutations in **KRAS** and **NRAS**; therefore, other MAPK pathway alterations known to drive resistance, such as other **KRAS** or **NRAS** mutations, **RAS** or **BRAF** amplifications, and **MEK** mutations, would not be detected. Furthermore, many (21%) of these patients exhibited emergence of multiple subclonal **RAS** mutations at progression, suggesting the potential for tumor heterogeneity in the context of acquired resistance to therapy. Indeed, a previous study by Kopetz and colleagues suggested that many **BRAF**

**V600E** colorectal cancers may harbor preexisting tumor subclones with 1 or more **RAS** mutations prior to therapy, leading to the potential for rapid emergence of heterogeneous resistant subclones (16).

Collectively, these observations raise an important conceptual issue: Even though the D+T+P combination contains a MEK inhibitor, many of the resistance signals driving resistance occur upstream of MEK, including RTK-driven feedback in primary resistance and MAPK pathway alterations upstream of MEK in acquired resistance. Theoretically, these signals should still be intercepted by the MEK inhibitor and should not lead to MAPK reactivation. In
targeted therapy paradigms, resistance alterations almost always occur at the level of or downstream of the drug target, not upstream. This finding highlights a key vulnerability of MEK inhibitors, i.e., increased upstream pathway flux can lead to MEK hyperactivation and a reduced ability of MEK inhibitors to maintain pathway suppression, which has been demonstrated in preclinical studies (28, 43). This also suggests that alternative strategies or agents capable of maintaining profound blockade of MAPK signaling may be key to enhancing activity in BRAFV600E colorectal cancer. We reported that ERK inhibitors, which act immediately downstream of MEK, can more effectively maintain MAPK suppression and can overcome many of the upstream resistance mechanisms to which MEK inhibitors are vulnerable (28, 32, 42). Thus, investigating ERK inhibitors or other agents that might achieve more robust and complete MAPK blockade may be key future strategies for BRAFV600E colorectal cancer.

Overall, our study provides an example of how identifying and targeting key adaptive feedback signals can overcome resistance and improve response in BRAFV600E colorectal cancer, although further optimization is needed. We observed MAPK reactivation as a consistent mechanism of both primary and acquired resistance, underscoring the MAPK pathway as a critical target in this disease. However, despite improvements in the response rate, the DOR is poor and median PFS is only 4.2 months. Our data suggest that rapid emergence of resistant subclones harboring MAPK-activating alterations may be a major driver of treatment failure and that future strategies aimed at suppressing or overcoming these resistance mechanisms may help to sustain clinical benefit. Such strategies might include next-generation targeted combinations or combinations with other classes of agents, such as cytotoxic chemotherapy, as was recently reported (40).

Prior studies, including The Cancer Genome Atlas, have demonstrated frequent associations between BRAFV600E mutation and MSI in colorectal cancer (24), with MSI status reported to affect prognosis in patients with BRAFV600E colorectal cancer (25). In the current study, many of the small group of patients who achieved prolonged benefit for >1 year while on therapy (including 3 patients who had a DOR ≥20 months) were noted to have MSI-high tumors. Similarly, the tumor from the 1 patient from our prior trial of dabrafenib and trametinib in BRAFV600E colorectal cancer who maintained a CR for >4 years was also MSI (17). Given recent data supporting the increased immunogenicity of MSI colorectal cancer and increased responsiveness to immune checkpoint inhibition (44–46), this observation suggests a potential role for the immune system in promoting durable response. Indeed, as data from melanoma and KRAS-mutant colorectal cancer suggest a potential synergy between MAPK inhibition and immune checkpoint inhibition (47, 48), combining optimal MAPK inhibition with immunotherapy may be a promising future strategy. Collectively, we hope that identifying and targeting key resistance mechanisms in BRAFV600E colorectal cancer will continue to lead to important improvements in clinical outcome for patients with this poor-prognosis molecular subtype of colorectal cancer.

METHODS

Study Design

This trial was an open-label, phase I study to investigate the safety, pharmacokinetics, pharmacodynamics, and clinical activity of trametinib and dabrafenib when administered in combination with the anti-EGFR antibody panitumumab in patients with BRAFV600E mutation–positive metastatic colorectal cancer (NCT01750918). Patients were enrolled to receive D+P, T+P, or D+T+P (Fig. 2) in initial dose-escalation studies to identify the optimal dosing strategy, followed by expansion cohorts to investigate the safety and clinical activity of each of the combination treatments. The appropriate ethics committee or Institutional Review Board at each study center approved the study protocol. The study was conducted in accordance with Guidelines for Good Clinical Practice and the ethical principles described in the Declaration of Helsinki, following all applicable local regulations.

Study Population

Eligible patients were required to have histologically or cytologically confirmed advanced or metastatic BRAFV600E mutation–positive colorectal cancer with measurable disease as per RECIST v1.1. BRAFV600E mutation status was determined by local testing. Patients were required to be aged ≥18 years, have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, have adequate baseline organ function (as determined by laboratory parameters), and be of non-child-bearing potential or agree to use contraception as outlined in the protocol. Key exclusion criteria included history of prior malignancy (other than colorectal cancer), BRAF mutation other than V600E, any serious or unstable preexisting medical condition, active hepatitis B or C infection, and prior exposure to a BRAF or MEK inhibitor. All patients provided written informed consent before enrollment.

Study Treatment

The study began with dose-escalation cohorts for all 3 drug combinations (D+P, D+T+P, and T+P) using a standard 3 + 3 enrollment scheme. Expansion cohorts were then enrolled to investigate the safety and clinical activity of the combinations. Patients in the D+P doublet arm were started in a dose-escalation cohort at the full monotherapy doses of dabrafenib (150 mg b.i.d.) and panitumumab (6 mg/kg Q2W; Fig. 1B). No dose de-escalations were required. Once the D+P dose was confirmed at the full dose of both agents, another cohort of patients was assigned to the D+T+P triplet arm. In the initial cohort, dabrafenib was started at full dose of 150 mg orally b.i.d., trametinib had a starting dose of 1.5 mg once daily, and panitumumab had a starting dose of 4.8 mg/kg i.v. Q2W. Dose escalation continued until the MTD was determined, and the full dose of all 3 agents was tested in the final cohort: dabrafenib 150 mg b.i.d., trametinib 2 mg orally daily, and panitumumab 6 mg i.v. Q2W. The DLT observation period was 28 days, and no DLTs were identified in the D+T+P cohort; the MTD was declared as the labeled dose of all 3 agents. Patients in the T+P arm, which included patients with BRAFV600E metastatic colorectal cancer and BRAF wild-type metastatic colorectal cancer with anti-EGFR therapy acquired resistance, received a starting dose of trametinib 2 mg once daily and panitumumab 6 mg/kg i.v. Q2W. No DLTs were identified in this cohort, but patients experienced delayed dermatologic toxicity with long-term dosing. Thus, sub-MTD doses were explored: trametinib 1.5 mg once daily and panitumumab 6 mg/kg i.v. Q2W; trametinib 2 mg once daily and panitumumab 4.8 mg/kg i.v. Q2W. Approximately 20 patients were then enrolled into expansion cohorts for each arm (including dose-escalation patients from selected dose groups). To further optimize the dose for the D+T+P arm, the protocol was later amended to explore the additional patients at 2 doses of panitumumab: 4.8 mg/kg i.v.
versus 6 mg i.v. Q2W. At the time of radiologic disease progression, patients in the D+P and T+P arms had the option of crossing over to the D+T+P arm.

**Study Assessments**

The primary endpoint was the safety of each of the drug combinations. Secondary endpoints included investigator-assessed overall response rate, DOR, PFS, OS, and the pharmacokinetics and pharmacodynamics of the drug combinations. All patients treated with the T+P combination (n = 51) were evaluated for safety, and the full safety data set for these patients was derived from this population. However, only 31 patients treated with T+P were BRAF mutant, and efficacy is reported only for this subset.

Patients received study therapy until disease progression, unacceptable toxicity, death, or discontinuation for any other reason. Patients were assessed weekly for the first 28 days of dosing and then every 4 weeks throughout the continuation period. Follow-up visits were conducted at 14 days, 4 weeks, and 8 weeks after study drug discontinuation and then subsequently every 8 weeks for survival follow-up. Safety was monitored throughout the study for all patients across cohorts via physical examinations, laboratory evaluations, vital sign and weight measurements, performance status evaluations, ocular and dermatologic examinations, concomitant medication monitoring, electrocardiograms, echocardiograms, and AE monitoring (characterized and graded per Common Terminology Criteria for Adverse Events, v4.0). AEs were recorded using standard Medical Dictionary for Regulatory Activities coding. Dose interruptions, reductions, and discontinuations for all of the study drugs were monitored.

Tumors were assessed using investigator-read CT or MRI at baseline, every 6 weeks until week 24, and then every 8 weeks until progression or death. Response determination was based on RECIST v1.1. In addition to imaging, the CEA tumor marker was collected. For the subset of patients who showed a confirmed CR or PR, DOR was defined as the time in weeks from the first documented evidence of CR or PR (the first response prior to confirmation) until the time of documented disease progression or death due to any cause, whichever was first. PFS was defined as the time in weeks between the first dose and the date of disease progression or death due to any cause. Finally, OS was defined as the time in weeks from the first dose of study drug until death due to any cause.

Serial blood samples for assessment of pharmacokinetic parameters were collected before dose and after dose on days 1 and 15 and before dose on day 21 in the first 28 days of dosing. In the continuation period, blood samples were collected every 4 weeks up to and including week 20 on study.

**Statistical Methods**

The all-treated population was used for analysis of clinical activity, which included all patients who received ≥1 dose of study medication. Patients evaluable for efficacy were defined as those who had ≥1 adequate post-baseline radiologic disease assessment. The pharmacokinetics population included all treated patients for whom a blood sample for pharmacokinetics analysis was available. The biomarker population was defined as the participants in the all-treated population for whom a tumor biopsy/tissue sample was obtained and analyzed. Analysis of patients who received an intrapatient dose escalation or who transferred from doublet to triplet therapy was included in the crossover population.

Dose-escalation phases of the study followed a 3 + 3 dose-escalation procedure. Evaluation of safety data from 23 patients who had completed 28 days of dosing on study was required prior to defining a new dose and starting the next cohort. To facilitate dose-escalation/de-escalation decisions, an adaptive Bayesian logistic regression model (BLRM) was used to predict the probability of DLTs at the dose levels yet to be tested. Specifically, an 8-parameter BLRM for combination treatment was fitted on the DLT data (i.e., absence or presence of DLT) accumulated throughout the dose-escalation phase to model the dose-toxicity relationship of D+T+P when given in combination (49).

Prior distributions for trametinib were calculated based on the toxicity data observed in the first-time-in-human study MEK111054, in which trametinib was administered alone. Similarly, prior distributions for dabrafenib were determined based on data observed in the first-time-in-human study BRF112680, in which dabrafenib was administered alone. Prior distributions of the parameter trametinib-dabrafenib interaction were based on data observed in study BRF113220, in which trametinib and dabrafenib were administered in combination. A noninformative prior was assumed for the other combination of the 2 or 3 compounds with panitumumab. The model was used only as a guide for what further doses to study in the presence of DLTs along with the 3 + 3 results.

The expansion phases of the study used a Bayesian predictive adaptive design that allowed the trial to be monitored more frequently at multiple stages (49). The criterion was based on a historically unimportant response rate of 15% versus a response rate of interest of 30%.

**Biomarker Analyses**

**Pharmacodynamic Analyses.** Fresh predose (baseline) and paired on-treatment (day 15) tumor biopsy specimens were collected and analyzed to assess the pharmacodynamic effects of each therapy. The MAPK pathway activation status was determined via immunohistochemistry assessment of pERK levels (Cell Signaling Technology; M0597, clone 20G11). In addition, pS6 (Cell Signaling Technology; M0341, clone D68F8) was also analyzed in a subset of the available fresh biopsy specimens at a sponsor-designated laboratory. For pERK and pS6, the H-score was derived as follows: [1 × (% cells 1) + 2 × (% cells 2) + 3 × (% cells 3)]. Nonparametric P values for the median differences between pretreatment and day 15 (±2) H-scores were derived for comparisons within and across arms.

**MSI Analyses.** Genomic DNA was isolated from tumor and non-tumor regions of tissue, and paired normal and tumor DNA were analyzed for MSI with 5 markers: BAT-25, BAT-26, NR-21, NR-24, and MONO-27. DNA was amplified by PCR. Fragment size distribution analysis was performed using high-resolution capillary electrophoresis with fluorescence detection. Fragment size distributions from tumor and nontumor tissue for each of the 5 markers were compared, and the stability or instability in size distribution patterns was determined. Significant changes in a marker indicate instability and imply a phenotypic decrease in tumor MMR activity. MSI status was reported as stable or high. In positive cases, 2 of 5 loci need to show instability. Instability was defined as variation of ≥3 bp PCR product size at the specific locus between nontumor and tumor samples. In a subset of samples, no sufficient normal DNA was available; MLH1, MSH2, MSH6, and PMS2 were analyzed immunohistochemically. If all markers stained positive, the tumor was considered to be MSS. If one of the markers was negative, the tumor was considered to be MSI.

We combined the confident calls that passed the quality-control criteria for MSI/MSS from both of the platforms. The box-plot comparisons across MSI/MSS were statistically assessed using the nonparametric Kruskal–Wallis P values. Time-to-event models stratifying based on MSI status were built, and Kaplan–Meier survival plots were assessed between MSI/MSS status using HR and 95% CIs and log-rank P values.

**cfDNA Analyses.** Plasma samples were collected at baseline, at week 4, and at progression. Baseline cfDNA and serial cfDNA collections were analyzed for the presence of mutations to provide correlates of response and to identify mechanisms of acquired resistance. Mutations were assessed in plasma cfDNA using BEAMing technology.
BRAF/EGFR/MEK Inhibition in BRAF<sup>V600E</sup> Colorectal Cancer


Conception and design: R.B. Corcoran, J.H.M. Schellens, J. Tabernero, P.J. O’Dwyer, J.C. Brase, B. Mookerjee, F. Rangwala

Development of methodology: R.B. Corcoran, J.H.M. Schellens, J. Tabernero, B. Mookerjee, F. Rangwala


Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): T. André, T. Yoshino, F. Rangwala


Acknowledgments

This study was supported by GlaxoSmithKline. As of March 2, 2015, dabrafenib and trametinib are assets of Novartis AG. R.B. Corcoran acknowledges support from a Damon Runyon Clinical Investigator Award and NIH/NCI P50 CA127003 and R01CA208437. This research was supported by a Stand Up To Cancer (SU2C) Colorectal Cancer Dream Team Translational Research Grant (Grant Number: SU2C-AACR-DT22-17). Stand Up To Cancer (SU2C) is a program of the Entertainment Industry Foundation. Research grants are administered by the American Association for Cancer Research, the scientific partner of SU2C. The authors acknowledge Yiquin Yan for biomarker statistical analyses, Kohinoor Dasgupta for clinical statistical analyses, and Ilona Tala for biomarker sample collection. Medical writing assistance was provided by William Fazzzone, PhD (ArticulateScience LLC), funded by Novartis Pharmaceuticals Corporation.

Received November 2, 2017; revised January 21, 2018; accepted January 30, 2018; published first February 5, 2018.

REFERENCES


Combined BRAF, EGFR, and MEK Inhibition in Patients with \(BRAF^{V600E}\)-Mutant Colorectal Cancer

Ryan B. Corcoran, Thierry André, Chloe E. Atreya, et al.

*Cancer Discov* 2018;8:428-443. Published OnlineFirst February 5, 2018.